AM ResearchBiomaterialsBioprinting

CELLINK’s FUNC bioink project receives €965K in EU funding

The three-year project is in collaboration with the Academisch Centrum Tandheelkunde Amsterdam

Swedish bioprinting company CELLINK has received SEK 10 million in funding (roughly €965,775) from the EU to pursue a bioink development project in collaboration with the Academisch Centrum Tandheelkunde Amsterdam (ACTA). The initiative is called the Functionalized Collagen-based Bioink for 3D Bioprinting project, or FUNC for short.

The FUNC project will take place over the next three years and has a total budget of SEK 19.5 million (€1,883,259). Half of the funding will be provided through Eurostars, a joint project between EUREKA and the European Commission which supports innovative projects led by R&D-performing SMEs that are marketable and have the potential to improve lives around the world.

The FUNC project will be aimed at developing a ready-to-use biofunctionalized collagen-based ink for bioprinting applications. According to CELLINK, the FUNC BIOINK will offer human cells the ideal biomimetic environment to thrive in thanks to the inclusion of peptides which promote cell attachment, spreading and direct differentiation.

CELLINK’s Bio X 3D bioprinter

The collagen-based bioink will ultimately be used to print a broad range of tissues for a number of different applications. For instance, the biomaterial’s versatility makes it suitable for academic research as well as cosmetic and pharmaceutical applications.

Within the bioprinting market, CELLINK has become something of a force to be reckoned with. In the past year alone, the company has amplified its position in the nascent bioprinting market with the acquisition of Dispendix, the release of many new bioink products and the announcement of a soon-to-be-released high-res holographic bioprinter with Prellis Biologics, Inc.

Not only that, the company has seen impressive financial success, with revenues of over $7 million (196% growth over the previous fiscal year) and a net turnover growth of 245%. Currently, the company offers four extrusion-based bioprinters (the INKREDIBLE, INKREDIBLE Plus, CELLINK GO and the high-end BIO X) and over 30 bioink materials. According to CELLINK CEO Erik Gatenholm, the company’s bioinks are the fastest growing revenue segment.


Tess Boissonneault

Tess Boissonneault moved from her home of Montreal, Canada to the Netherlands in 2014 to pursue a master’s degree in Media Studies at the University of Amsterdam. It was during her time in Amsterdam that she became acquainted with 3D printing technology and began writing for a local additive manufacturing news platform. Now based in France, Tess has over two and a half years experience writing, editing and publishing additive manufacturing content with a particular interest in women working within the industry. She is an avid follower of the ever-evolving AM industry.

Related Articles

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*